Associations - STK11 mutation

STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Lung Cancer - 5 days (New C3)	Immunotherapy Resistant: C3 – Early Trials Lung Cancer - 5 days - (New C3)
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	nivolumab Resistant: B - Late Trials	nivolumab Resistant: B - Late Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	DRP-104 Sensitive: B - Late Trials	DRP-104 Sensitive: B - Late Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: B - Late Trials	durvalumab Resistant: B - Late Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Resistant: B - Late Trials	atezolizumab Resistant: B - Late Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	BGB324 Sensitive: B - Late Trials	BGB324 Sensitive: B - Late Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab + BGB324 Sensitive: B - Late Trials	pembrolizumab + BGB324 Sensitive: B - Late Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: B - Late Trials	bevacizumab + atezolizumab Sensitive: B - Late Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials	docetaxel Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials	atezolizumab Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials	camrelizumab + rivoceranib Sensitive: C3 – Early Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	cetuximab + avelumab Resistant: C3 – Early Trials	cetuximab + avelumab Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: C3 – Early Trials	durvalumab + CP-675206 Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	durvalumab Resistant: C3 – Early Trials	durvalumab Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Cervical Cancer Cervical Cancer	STK11 mutation STK11 mutation	Cervical Cancer Cervical Cancer	anlotinib + sintilimab Resistant: C3 – Early Trials	anlotinib + sintilimab Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Solid Tumor Solid Tumor	STK11 mutation STK11 mutation	Solid Tumor Solid Tumor	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide + capecitabine Resistant: C4 – Case Studies	temozolomide + capecitabine Resistant: C4 – Case Studies
STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	everolimus Sensitive: C4 – Case Studies	everolimus Sensitive: C4 – Case Studies
STK11 mutation STK11 mutation	Pancreatic Cancer Pancreatic Cancer	STK11 mutation STK11 mutation	Pancreatic Cancer Pancreatic Cancer	everolimus Sensitive: C4 – Case Studies	everolimus Sensitive: C4 – Case Studies
STK11 mutation STK11 mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	STK11 mutation STK11 mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Resistant: C4 – Case Studies	pembrolizumab Resistant: C4 – Case Studies
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	abemaciclib Sensitive: C4 – Case Studies	abemaciclib Sensitive: C4 – Case Studies
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	APG-115 Sensitive: D – Preclinical	APG-115 Sensitive: D – Preclinical
STK11 mutation STK11 mutation	Lung Cancer Lung Cancer	STK11 mutation STK11 mutation	Lung Cancer Lung Cancer	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical
STK11 mutation STK11 mutation	Lung Cancer Lung Cancer	STK11 mutation STK11 mutation	Lung Cancer Lung Cancer	dasatinib Resistant: D – Preclinical	dasatinib Resistant: D – Preclinical
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	sirolimus Sensitive: D – Preclinical	sirolimus Sensitive: D – Preclinical
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	CI-1040 Sensitive: D – Preclinical	CI-1040 Sensitive: D – Preclinical
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	JQ-1 Resistant: D – Preclinical	JQ-1 Resistant: D – Preclinical